Novavax does not have a forecast for U.S. orders in 2022: CEO Erck

Novavax does not have a forecast for U.S. orders in 2022: CEO Erck

Novavax (NVAX) missed Wall Street expectations Monday after its second quarter earnings showed softer-than-expected demand in global vaccine sales, forcing the company to slash its 2022 outlook by 50% to $2 billion.

While at least $400 million in revenue has come in since July 1, the company has not fulfilled orders for low- and middle-income countries (LMICs) through the global COVAX program and anticipates no further orders from the U.S. this year, according to company executives Monday.

But…


Source link

About search

Check Also

European Stocks Drop With US Tech Rally Faltering: Markets Wrap – Yahoo Finance

European Stocks Drop With US Tech Rally Faltering: Markets Wrap – Yahoo Finance

[unable to retrieve full-text content]European Stocks Drop With US Tech Rally Faltering: Markets Wrap  Yahoo Finance …

Leave a Reply

Your email address will not be published. Required fields are marked *